<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502199</url>
  </required_header>
  <id_info>
    <org_study_id>MECP2BOYS (29BRC20.0182)</org_study_id>
    <nct_id>NCT04502199</nct_id>
  </id_info>
  <brief_title>Dysautonomic Phenotype in Male Patients With MECP2 Mutation</brief_title>
  <acronym>MECP2BOYS</acronym>
  <official_title>Dysautonomic Signs Among MECP2boys</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysautonomic signs are well known among girls with a Rett Syndrom. Rett syndrom is caused by&#xD;
      a MECP2 mutation in 95% of cases. We want to search dysautonomic signs among boys with a&#xD;
      MECP2 mutations because they are less studied than the girls and they have more varied&#xD;
      phenotypes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First, we will launch a national call for participation in all the genetics departments in&#xD;
      France to research boys with a missense or a non-sens mutation in the MECP2 gene. Our&#xD;
      inclusion criteria is : less than 16 years old or dead before 16 years old patients of&#xD;
      masculin sex with a missense or non-sens mutation in the MECP2 gene. Exclusion criteria is :&#xD;
      patient under judicial protection or participation refusal by one of the legal guardian.&#xD;
      Inclusion will take place in August 2020.&#xD;
&#xD;
      We had conceived an excel spreadsheet (2007 version) to collect all the datas needed with&#xD;
      general data such as age, genetic mutation with the HGVS nomenclature using the&#xD;
      NM_001110792.2, familial and personal history, mensurations, dysmorphic signs. To search&#xD;
      dysautonomic signs, we used a system approach. We will look for neurological signs : abnormal&#xD;
      movements, sleep disturbance, cardiologic signs :abnormal bradycardia or tachycardia,&#xD;
      hypotension, rythms anomalies, respiratory signs : respiratory irregularities, apnea,&#xD;
      hyperpnea , digestive signs : gastrooesophagal reflux, constipation, diarrhea, vomiting or&#xD;
      subocclusif episodes, thermoregulation signs : abnormal hypo or hyperthermia, excessive&#xD;
      sweating. Each time a dysautonomic sign will be reported in a letter of a patient, we will&#xD;
      demand this sign to be objectived by a complementary exam, or by a precise device during an&#xD;
      hospitalisation : electoencephalogram (EEG), polysomnography (PSG), Electrocardiogram (ECG),&#xD;
      holter-ECG, digestive fibroscopies, scoped surveillance.&#xD;
&#xD;
      If we have a positive response, we will contact the main caregiver of the patient who can be&#xD;
      a neurologist or a geneticist and will provid him a spreadsheet and an explanatory sheet. We&#xD;
      will ask of him a systematic review of all the letters of the patient including letters of&#xD;
      hospitalisation, of the specialists, complementary exams. A non-opposition letter will be&#xD;
      sent to him in a way he can send it to the legal guardians of the children : a non-opposition&#xD;
      of 15 days will be requested. Then, the filled spreadsheet will be sent back to the center of&#xD;
      inclusion in Brest through a securised mailbox. Data will be kept on a secure database with a&#xD;
      password.&#xD;
&#xD;
      Our primary endpoint is the presence of at least one dysautonomic sign. We intend to include&#xD;
      between 10 and 20 patients in this multicentric study. To analyse our results, we will use a&#xD;
      descriptive approach.&#xD;
&#xD;
      This protocole was validated by the Ethic Comitee of Brest in june 18, 2020&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">January 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>presence of at least one dysautonomic sign</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>MECP2-Related Severe Neonatal Encephalopathy</condition>
  <condition>Dysautonomia</condition>
  <condition>Masculinity</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non interventional study</intervention_name>
    <description>observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        less than 16 years old or dead before 16 years old patients of masculin sex with a missense&#xD;
        or non-sens mutation in the MECP2 gene&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:less than 16 years old or dead before 16 years old patients of masculin&#xD;
        sex with a missense or non-sens mutation in the MECP2 gene -&#xD;
&#xD;
        Exclusion Criteria:patient under judicial protection or participation refusal by one of the&#xD;
        legal guardian&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Juliette ROPARS</last_name>
    <phone>0298223657</phone>
    <email>juliette.ropars@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>DELPLANCQ DELPLANCQ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Juliette ROPARS</last_name>
      <email>juliette.ropars@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>PETIT PETIT</last_name>
      <email>Florence.petit@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civiles de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaetan LESCA,</last_name>
      <email>gaetan.lesca@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent DESPORTES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorothée VILLE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu MILH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NIMES</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie FARMER,</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine SARRET</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Rett Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning six months and ending five years following the end study</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

